#16
|
||||
|
||||
Öèòàòà:
"Changes in percutaneous coronary intervention over the last 20 years: demographic, epidemiologic and clinical characteristics, techniques, and outcomes" [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ìíå êàæåòñÿ âñå çàâèñèò îò ïðîôèëÿ îòäåëåíèÿ èëè êëèíèêè. Åñòü "ñêîðîïîìîùíûå" áîëüíèöû ñ ñîîòâåòñòâóþùèì êîíòèíãåíòîì, åñòü ïëàíîâûå îòäåëåíèÿ â ñîñòàâå êàðäèîõèðóðãè÷åñêèõ êëèíèê, åñòü ïðîìåæóòî÷íûå âàðèàíòû. Åñëè ãîâîðèòü â ïðèíöèïå, òî ÿ çà òî, ÷òî áû â ÷àñòè ñîìíèòåëüíûõ ñëó÷àåâ, êîãäà íå óäàåòñÿ îïðîâåðãíóòü äèàãíîç ÈÁÑ íåèíâàçèâíûìè ñïîñîáàìè ïðîâîäèòü ÊÀÃ.  ýòîé ñèòóàöèè îáíàðóæåíèå àíãèîãðàôè÷åñêè "÷èñòûõ" êîðîíàðíûõ àðòåðèé, íå ÿâëÿåòñÿ ñâèäåòåëüñòâîì î íèçêîé êâàëèôèêàöèè êàðäèîëîãà. Ýòî óæå êàê-òî îáñóæäàëîñü. |
#17
|
||||
|
||||
Öèòàòà:
Öèòàòà:
|
#18
|
|||
|
|||
âîçìîæíî, êîãî-òî çàèíòåðåñóåò [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#19
|
|||
|
|||
EVAR äîáðàëñÿ äî NEJM
1. Ýíäîâàñêóëÿðíîå ëå÷åíèå íå óñòóïàåò îòêðûòîé õèðóðãèè ïðè äëèòåëüíîì íàáëþäåíèè - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 2. Ðåçóëüòàòû ñõîæåãî ñ EVAR èññëåäîâàíèÿ DREAM (Ãîëëàíäèÿ) - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 3. Íî îêàçûâàåòñÿ, ÷òî ïðè îòñóòñòâèè âîçìîæíîñòè ïðîâåäåíèÿ îòêðûòîé îïåðàöèè, ýíäîâàñêóëÿðíîå ëå÷åíèå èìååò ìàëî ïðåèìóùåñòâ ïî ñðàâíåíèþ ñ êîíñåðâàòèâíîé òàêòèêîé ïî âëèÿíèþ íà ñìåðòíîñòü - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Êàê-òî ýòî íå î÷åíü óêëàäûâàåòñÿ â ãîëîâå. Ñåðãåé Àëåêñàíäðîâè÷, ïðîêîììåíòèðóéòå, ïîæàëóéñòà, î÷åíü èíòåðåñíû Âàøè ìûñëè ïî ýòîìó ïîâîäó. Ýòî "ñòàðûå" ïðîòåçû â EVAR? Ïðèíöèïèàëüíîå íåñîâåðøåíñòâî òåõíîëîãèè ñòåíòèðîâàíèÿ èëè ÷òî-òî åùå? Êóäà æå âñ¸ òàêè íàïðàâëÿòü ïàöèåíòà ñ AAA >5.5 ñì, íà ñòåíòèðîâàíèå èëè ê õèðóðãàì? |
#20
|
|||
|
|||
Öèòàòà:
|
#21
|
||||
|
||||
Öèòàòà:
Ñòåíòèðîâàíèå ãðóäíûõ àíâåðèçì - ïðåêðàñíî.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#22
|
|||
|
|||
ISAR-DESIRE 2
Ïîêà íà ñîñåäíåé âåòêå èäåò àêòèâíîå îáñóæäåíèå DEB, â JACC îïóáëèêîâàíî ñðàâíåíèå SES ïðîòèâ PES ïðè ëå÷åíèè ðåñòåíîçîâ - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Àâòîðû èç Ãåðìàíèè äåëàþò âûâîä î ñðàâíèìîñòè ýòèõ äâóõ òèïîâ ñòåíòîâ. |
|
#23
|
|||
|
|||
DEDICATION
 JACC îïóáëèêîâàíû ðåçóëüòàòû ñðàâíèòåëüíîãî èññëåäîâàíèÿ (DES vs BMS) ó ïàöèåíòîâ ñ ÈÌ ñ ïîäúåìîì ST - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Results At 3 years, target lesion revascularization was 6.1% in the DES group compared with 16.3% in the BMS group (p < 0.001), and the rate of major adverse cardiac events was 11.5% versus 18.2%, respectively (p = 0.02). Whereas all-cause mortality did not differ significantly, the rate of cardiac death was higher in the DES group, 6.1% versus 1.9% for the BMS group (p = 0.01). The occurrence of reinfarction, stroke, and stent thrombosis was similar. |
#24
|
||||
|
||||
Èíòåðåñíî, à ÷òî ìû áîëüøå ëþáèì, ðåñòåíîç èëè ñìåðòü?
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#25
|
||||
|
||||
|
#26
|
||||
|
||||
|
#27
|
|||
|
|||
×ðåñêîæíàÿ èìïëàíòàöèÿ àîðòàëüíîãî êëàïàíà (PARTNER)
 NEJM îïóáëèêîâàíû ðåçóëüòàòû äîëãîæäàííîãî èññëåäîâàíèÿ PARTNER.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äîëãîæäàííîãî, ïîòîìó ÷òî ýòî ïåðâîå ðàíäîìèçèðîâàííîå ñðàâíåíèå ÷ðåñêîæíî èìïëàíòèðóåìîãî àîðòàëüíîãî êëàïàíà (TAVI) ñ òðàäèöèîííîé òåðàïèåé (áàëîííàÿ âàëüâóëîïëàñòèêà+ìåäèêàìåíòîçíàÿ òåðàïèÿ). Èññëåäîâàíèå ñîñòîèò èç äâóõ ÷àñòåé. Ãðóïïà À: TAVI ïðîòèâ îòêðûòîé õèðóðãèè; ãðóïïà Â: TAVI ïðîòèâ òðàäèöèîííîé òåðàïèè. Äîëîæåíû ðåçóëüòàòû ïî ãðóïïå Â. Ïî ìíåíèþ àâòîðîâ èññëåäîâàíèÿ "àt 1 year, the rate of death from any cause (Kaplan–Meier analysis) was 30.7% with TAVI, as compared with 50.7% with standard therapy (hazard ratio with TAVI, 0.55; 95% confidence interval [CI], 0.40 to 0.74; P<0.001)". Ìàëåíüêàÿ ëîæêà ä¸ãòÿ: â ñòàòüå íå÷åòêî îïèñàíà ïðîöåäóðà ðàñïðåäåëåíèÿ ïàöèåíòîâ ìåæäó ãðóïïàìè TAVI è òðàäèöèîííîé òåðàïèè. |
#28
|
|||
|
|||
Êðàñèâî, ïîíÿòíî îá Ð×À
Cardiac Anatomy for the Interventional Arrhythmologist:I.Terminology and Fluoroscopic Projections
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#29
|
|||
|
|||
Ýíäîâàñêóëÿðíîå ëå÷åíèå àíåâðèçì è äèññåêöèé ãðóäíîãî îòäåëà àîðòû (îáçîð)
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#30
|
|||
|
|||
Percutaneous Mechanical Assistance for the Failing Heart (îáçîð)
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |